Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors

The goal of this prospective, multicenter, single-arm clinical study is to evaluate the efficacy and safety of toripalimab in combination with axitinib for postoperative adjuvant therapy for non-clear renal cell carcinoma with high-risk recurrence factors.

Trial Details

NCT ID
NCT05768464
Phase
PHASE2
Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • Toripalimab
  • Axitinib
Locations (sample)
  • Nanjing, Jiangsu, China|32.06167,118.77778
  • Nanning, Jiangsu, China

Key Eligibility Criteria

  • Age 18-75 years old
  • Participants with histologically confirmed non-clear renal cell carcinoma except clear cell RCC, chromophobe RCC and eosinophilic RCC, and must mee…
  • histologically confirmed Papillary RCC, pT≥T1b and ISUP/WHO ≥3, N (any), M0;
  • Collecting duct carcinoma, SMARCB1-deficient renal medullary carcinoma, fumarate hydratase deficiency renal cell carcinoma (FH-RCC), pT (any), ISUP…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →